{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:03:08Z","timestamp":1791270188955,"version":"4.1.0"},"reference-count":153,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T00:00:00Z","timestamp":1452211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:p>\n                    Type 2 diabetes (\n                    <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                    ) is a progressive disease, and pharmacotherapy with a single agent does not generally provide durable glycaemic control over the long term. Sulphonylurea (\n                    <jats:styled-content style=\"fixed-case\">SU<\/jats:styled-content>\n                    ) drugs have a history stretching back over 60 years, and have traditionally been the mainstay choice as second\u2010line agents to be added to metformin once glycaemic control with metformin monotherapy deteriorates; however, they are associated with undesirable side effects, including increased hypoglycaemia risk and weight gain. Dipeptidyl peptidase (\n                    <jats:styled-content style=\"fixed-case\">DPP<\/jats:styled-content>\n                    )\u20104 inhibitors are, by comparison, more recent, with the first compound being launched in 2006, but the class now globally encompasses at least 11 different compounds.\n                    <jats:styled-content style=\"fixed-case\">DPP<\/jats:styled-content>\n                    \u20104 inhibitors improve glycaemic control with similar efficacy to\n                    <jats:styled-content style=\"fixed-case\">SUs<\/jats:styled-content>\n                    , but do not usually provoke hypoglycaemia or weight gain, are relatively free from adverse side effects, and have recently been shown not to increase cardiovascular risk in large prospective safety trials. Because of these factors,\n                    <jats:styled-content style=\"fixed-case\">DPP<\/jats:styled-content>\n                    \u20104 inhibitors have become an established therapy for\n                    <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                    and are increasingly being positioned earlier in treatment algorithms. The present article reviews these two classes of oral antidiabetic drugs (\n                    <jats:styled-content style=\"fixed-case\">DPP<\/jats:styled-content>\n                    \u20104 inhibitors and\n                    <jats:styled-content style=\"fixed-case\">SUs<\/jats:styled-content>\n                    ), highlighting differences and similarities between members of the same class, as well as discussing the potential advantages and disadvantages of the two drug classes. While both classes have their merits, the choice of which to use depends on the characteristics of each individual patient; however, for the majority of patients,\n                    <jats:styled-content style=\"fixed-case\">DPP<\/jats:styled-content>\n                    \u20104 inhibitors are now the preferred choice.\n                  <\/jats:p>","DOI":"10.1111\/dom.12610","type":"journal-article","created":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T02:48:55Z","timestamp":1448333335000},"page":"333-347","source":"Crossref","is-referenced-by-count":186,"title":["Comparative review of dipeptidyl peptidase\u20104 inhibitors and sulphonylureas"],"prefix":"10.1111","volume":"18","author":[{"given":"C. F.","family":"Deacon","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences University of Copenhagen  Copenhagen N Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. E.","family":"Lebovitz","sequence":"additional","affiliation":[{"name":"State University of New York Health Science Center  Brooklyn NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,1,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.9.1126"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.9.2181"},{"key":"e_1_2_7_4_1","first-page":"17","article-title":"Pharmacology of GLP\u20101\u2010based therapies","author":"Deacon CF","year":"2008","journal-title":"Review of Endocrinology"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.47.11.1663"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3460-0"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP.15.6.540"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP13176.CS"},{"key":"e_1_2_7_9_1","unstructured":"Latin American Diabetes Association.Treatment of type 2 diabetes in Latin America: Latin American Diabetes Association consensus statement. Available from URL:http:\/\/issuu.com\/alad\u2010diabetes\/docs\/guias_alad_2013. Accessed 31 July 2015."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00577838"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-0115(99)00089-0"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm050261p"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm030091l"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsb882"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1327.2000.01617.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(02)01059-4"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.10.2988"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00860.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm070104l"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2011.09.043"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S65678"},{"key":"e_1_2_7_22_1","unstructured":"HwangDM KimSH. Kim et al. LC15\u20100444 is a novel potent selective and orally active dipeptidyl peptidase IV inhibitor.Poster presented at the 68th American Diabetes Association Scientific Sessions San Francisco 2008; Poster 502\u2010P. Available from URL:http:\/\/professional.diabetes.org\/Content\/Posters\/2008\/p502\u2010P.pdf. Accessed 13 October 2015."},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm701280z"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm401992e"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0493156"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2012.08.012"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.06.008"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2502"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-013-0024-0"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S16925"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01610.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305889"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01306.x"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0496-5"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2013.865856"},{"key":"e_1_2_7_38_1","unstructured":"XuS KauhA TatosianDet al. Absorption metabolism and excretion of [14C]omarigliptin a once\u2010weekly DPP\u20104 inhibitor in humans.Poster presented at 74th American Diabetes Association Scientific Sessions San Francisco 2014; Poster 1080\u2010P. Available from the ADA ePoster archives via URL:https:\/\/ada.scientificposters.com\/epsSearchADA.cfm. Accessed 27 October 2015."},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2013.816891"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0431-9"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2012.731618"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01414.x"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.03.010"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-013-0045-8"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.04.001"},{"key":"e_1_2_7_46_1","unstructured":"Japanese Pharmaceuticals and Medical Devices Agency.Teneligliptin review report. Available from URL:http:\/\/www.pmda.go.jp\/files\/000153594.pdf. Accessed 30 July 2015."},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.062331"},{"key":"e_1_2_7_48_1","unstructured":"European Medicines Agency.Alogliptin; Summary of product characteristics. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002182\/WC500152271.pdf. Accessed 30 July 2015."},{"key":"e_1_2_7_49_1","unstructured":"Anagliptin; Prescribing information 2015. Available from URL:http:\/\/www.rad\u2010ar.or.jp\/siori\/english\/kekka_plain.cgi?n=32790. Accessed 30 July 2015."},{"key":"e_1_2_7_50_1","unstructured":"European Medicines Agency.Linagliptin; Summary of product characteristics. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002110\/WC500115745.pdf. Accessed 30 July 2015."},{"key":"e_1_2_7_51_1","unstructured":"European Medicines Agency.Saxagliptin; Summary of product characteristics. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/001039\/WC500044316.pdf. Accessed 30 July 2015."},{"key":"e_1_2_7_52_1","unstructured":"Omarigliptin; Japanese prescribing information 2015. Available from URl:https:\/\/www.msdconnect.jp\/static\/mcijapan\/images\/pi_marizev_tab.pdf. Accessed 27 October 2015."},{"key":"e_1_2_7_53_1","unstructured":"European Medicines Agency.Sitagliptin; Summary of product characteristics. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000722\/WC500039054.pdf. Accessed 30 July 2015."},{"key":"e_1_2_7_54_1","unstructured":"Japanese Pharmaceuticals and Medical Devices Agency.Teneligliptin; Review report. Available from URL:http:\/\/www.pmda.go.jp\/files\/000153594.pdf. Accessed 30 July 2015."},{"key":"e_1_2_7_55_1","unstructured":"Trelagliptin; Japanese prescribing information 2015. Available from URL:http:\/\/www.takedamed.com\/content\/medicine\/pdf\/zafatek.pdf. Accessed 30 July 2015."},{"key":"e_1_2_7_56_1","unstructured":"European Medicines Agency.Vildagliptin; Summary of product characteristics. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000771\/WC500020327.pdf. Accessed 30 July 2015."},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-S014"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12295"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.2165\/11584350-000000000-00000"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04173.x"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01214.x"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-014-0061-3"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12429"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12060"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.1114"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2009.01.004"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2012.06.001"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0199"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3655-z"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70251-7"},{"key":"e_1_2_7_71_1","first-page":"S55","article-title":"Effect of omarigliptin, a novel once\u2010weekly DPP\u20104 inhibitor, in Japanese patients with type 2 diabetes: a placebo\u2010 and sitagliptin\u2010controlled trial","volume":"57","author":"Gantz I","year":"2014","journal-title":"Diabetologia"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.824966"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1314078"},{"key":"e_1_2_7_74_1","unstructured":"ADA\/EASD\/IDF recommendations for clinicians and people with diabetes concerning the use of incretin therapy and pancreatic disease. Available from URL:http:\/\/easd.org\/index.php?option=com_content&view=article&id=172. Accessed 6 March 2015."},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2546"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3231-y"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098614523031"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.010389"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62225-X"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.6.5.408"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118387658.ch42"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5239.1166"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2008.0142"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.47.9.1412"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01507.x"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.123224"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565030-00005"},{"key":"e_1_2_7_88_1","unstructured":"Electronic Medicines Compendium (eMC).Glibenclamide; Summary of product characteristics. Available from URL:http:\/\/www.medicines.org.uk\/emc\/medicine\/30411. Accessed 30 July 2015."},{"key":"e_1_2_7_89_1","unstructured":"Electronic Medicines Compendium (eMC).Gliclazide; Summary of product characteristics. Available from URL:http:\/\/www.medicines.org.uk\/emc\/medicine\/25838. Accessed 30 July 2015."},{"key":"e_1_2_7_90_1","unstructured":"Electronic Medicines Compendium (eMC).Glimepiride; Summary of product characteristics. Available from URL:http:\/\/www.medicines.org.uk\/emc\/medicine\/25845. Accessed 30 July 2015."},{"key":"e_1_2_7_91_1","unstructured":"Electronic Medicines Compendium (eMC).Glipizide; Summary of product characteristics. Available from URL:http:\/\/www.medicines.org.uk\/emc\/medicine\/9851. Accessed 30 July 2015."},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01496.x"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12287"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.235"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1789"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2470"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1103053"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03657.x"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0600"},{"key":"e_1_2_7_100_1","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0468"},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003795"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.1136\/heart.90.1.9"},{"key":"e_1_2_7_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12456"},{"key":"e_1_2_7_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-051X.1988.tb01003.x"},{"key":"e_1_2_7_105_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-9-201211060-00003"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12232"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12302"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0719"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020904"},{"key":"e_1_2_7_110_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00024.2007"},{"key":"e_1_2_7_111_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr077"},{"key":"e_1_2_7_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2014.09.047"},{"key":"e_1_2_7_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70213-X"},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068294"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc070546"},{"key":"e_1_2_7_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02353.x"},{"key":"e_1_2_7_117_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.02938.x"},{"key":"e_1_2_7_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60691-6"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2012.0272"},{"key":"e_1_2_7_120_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00704.x"},{"key":"e_1_2_7_121_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.568059"},{"key":"e_1_2_7_122_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.703134"},{"key":"e_1_2_7_123_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-014-0082-y"},{"key":"e_1_2_7_124_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12419"},{"key":"e_1_2_7_125_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12179"},{"key":"e_1_2_7_126_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150130120747"},{"key":"e_1_2_7_127_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12319"},{"key":"e_1_2_7_128_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-015-0271-z"},{"key":"e_1_2_7_129_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12461"},{"key":"e_1_2_7_130_1","first-page":"52","volume-title":"Non\u2010Insulin\u2010Dependent Diabetes Mellitus","author":"Turner RC","year":"1989"},{"key":"e_1_2_7_131_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066224"},{"key":"e_1_2_7_132_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12445"},{"key":"e_1_2_7_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2015.03.007"},{"key":"e_1_2_7_134_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12489"},{"key":"e_1_2_7_135_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12116"},{"key":"e_1_2_7_136_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12306"},{"key":"e_1_2_7_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2015.02.002"},{"key":"e_1_2_7_138_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124287"},{"key":"e_1_2_7_139_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164115570301"},{"key":"e_1_2_7_140_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2007.00744.x"},{"key":"e_1_2_7_141_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2152"},{"key":"e_1_2_7_142_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2072"},{"key":"e_1_2_7_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2005.07.009"},{"key":"e_1_2_7_144_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0798"},{"key":"e_1_2_7_145_1","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0805"},{"key":"e_1_2_7_146_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0627"},{"key":"e_1_2_7_147_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.405"},{"key":"e_1_2_7_148_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061759"},{"key":"e_1_2_7_149_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2000.00305.x"},{"key":"e_1_2_7_150_1","doi-asserted-by":"publisher","DOI":"10.2337\/db07-0440"},{"key":"e_1_2_7_151_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2319-x"},{"key":"e_1_2_7_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2011.10.018"},{"key":"e_1_2_7_153_1","doi-asserted-by":"publisher","DOI":"10.2165\/11532980-000000000-00000"},{"key":"e_1_2_7_154_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0356"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12610","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12610","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:57:47Z","timestamp":1761865067000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,8]]},"references-count":153,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/dom.12610"],"URL":"https:\/\/doi.org\/10.1111\/dom.12610","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,8]]}}}